Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Nutrition and Dietetics Drug Data - A-Z (English)
Drug Class Description
Calcium supplements.Generic Name
Calcium - nutritionDrug Description
Sandocal 400: white effervescent tablets. Sandocal 1000: white effervescent tablets.Presentation
Sandocal 400: Calcium lactate gluconate 930 mg, calcium carbonate 700 mg providing calcium 400 mg (10 mmol), citric acid 1 .189 g. Sandocal 1000: Calcium lactate gluconate 2.327 g, calcium carbonate 1.75 g providing calcium 1 g (25 mmol), citric acid 2.973 g.Indications
Adjunct in osteoporosis, supplement in dietary calcium deficiency or where requirements are high.Adult Dosage
Sandocal 1000mg
Adults and children: 1000mg per day.
The effervescent tablets should be dissolved in a glass of water (approx. 200 ml) and drunk immediately. Sandocal 1000 effervescent tablet may be taken with or without food.
Distinguish between adults, children and the elderly and between different clinical indications.
Treatment of therapeutic supplementation should aim to restore or maintain normal levels of calcium (2.25 - 2.75mmol/l or 4.5 - 5.5meq/l).
Sandocal 400
Adults
Osteoporosis: 3-4 tablets/day.
Therapeutic supplement
(dose dependent upon severity): 1-4 tablets/day (dose dependent upon severity).
Child Dosage
Calcium deficiency: 1-2 tablets/day.
Dietary supplementation: 1 tablet/day.
Elderly Dosage
No evidence exists that tolerance is directly affected by advanced age. Elderly patients should be supervised, as factors sometimes associated with ageing, such as poor diet or renal function, may indirectly affect tolerance and may require dosage adjustment
Contra Indications
Hypercalcaemia (eg in hyperparathyroidism, vitamin D overdosage, decalcifying tumours such as plasmocytoma, severe renal failure, bone metastases), severe hypercalciuria and renal calculi.
Special Precautions
In mild hypercalciuria exceeding 300mg (7.5mmol) per 24 hours, or renal failure, or where there is evidence of stone formation in the urinary tract, adequate checks must be kept on urinary calcium excretion; if necessary the dosage should be reduced or calcium therapy discontinued.
Interactions
High vitamin D intake should be avoided unless especially indicated (see also Overdosage section). Thiazide diuretics reduce urinary calcium excretion so the risk of hypercalcaemia, should be considered.
Oral calcium supplementation is aimed at restoring normal calcium serum levels. Although it is extremely unlikely that high enough levels will be achieved to adversely affect digitalised patients, this theoretical possibility should be considered.
Oral calcium administration may reduce the absorption of oral tetracycline or fluoride preparations. An interval of 3 hours should be observed if the two are to be given.
Adverse Reactions
Mild gastrointestinal disturbances (eg constipation, diarrhoea) have occurred rarely. Although hypercalcaemia would not be expected in patients unless their renal function were impaired, the following symptoms could indicate the possibility of hypercalcaemia: nausea, vomiting, anorexia, constipation, abdominal pain, bone pain, thirst, polyuria, muscle weakness, drowsiness or confusion.
Manufacturer
Novartis Consumer HealthDrug Availability
(P)Updated
09 June 2009Advert for Healthcare Professionals Only
Latest News
12th February 2012
Cyberknife (Accuray Inc) relieves pain of Trigeminal Neuralgia facial nerve condition Page
Cyberknife, the Intensity Modulated RadioTherapy system from Accuray Inc, can relieve the stabbing pain of the facial nerve condition Trigeminal Neuralgia. Researchers treated 17 patients with Trigeminal Neuralgia with Cyberknife radiosurgery between 2007 and 2009. The patients, who were aged between 36 and 90, had had their symptoms for between one and 11 years and had not responded to the available treatment options. The researchers zapped a 6mm length of trigeminal nerve, just 2 to 3mm from the root, using a maximum radiation dose of 73.06 Gy. The patients were then monitored regularly after the procedure, for an average of just under 12 months. Complete data were available for 16 patients, 14 of whom obtained either partial or complete relief from their symptoms. The average time before symptom relief occurred was just under two months, but varied from three weeks to six months. Four patients relapsed after the procedure, between three and 18 months later. No patient experienced major complications as a result of the procedure, and only two patients reported any sensory side effects. See: >"Cyberknife radiosurgery in treating trigeminal neuralgia" by Bryan M Lazzara et al. Journal of NeuroInterventional Surgery (2012). doi:10.1136/neurintsurg-2011-010125
FDA approves trial of Celution System (Cytori Therapeutics) for CMI Cardiology Page
Cytori Therapeutics has received an Investigational Device Exemption (IDE) approval from the FDA to begin the ATHENA trial using its Celution System. ATHENA will investigate the use of the Celution System to treat a form of Coronary Heart Disease, Chronic Myocardial Ischemia (CMI). The IDE application was originally submitted to the FDA in December 2011. The trial will enroll up to 45 patients with no-option CMI who have limited therapeutic options. It will evaluate a variety of clinical and functional outcomes, including safety, peak oxygen consumption (mVO2), and clinical outcomes at 12-months.
Phase III Trial of MDV 3100 (Medivation/Astellas) in Prostate Cancer patients shows positive results Oncology Page
Researchers have presented positive results on all efficacy endpoints from the Phase III AFFIRM trial of the investigational drug MDV 3100, from Medivation and Astellas, in men with Prostate Cancer previously treated with chemotherapy. The results, presented at the 2012 Genitourinary Cancers Symposium, show that men taking MDV 3100 lived for a median of 18.4 months, compared with 13.6 months for men taking placebo. MDV 3100 also met all secondary endpoints, including radiographic progression-free survival (8.3 versus 2.9 months; PSA declines of 50% or greater were more common in the MDV 3100 group than in the placebo group (54.0% versus 1.5%; and MDV 3100 was found to be well tolerated. The data was presented by Howard I. Scher, chief, Genitourinary Oncology Service at Memorial-Sloan Kettering Cancer Center.
